Menu ×


CDK 4/6 Inhibitor Drugs Market Segmentation By Product Type (Palbociclib, Ribociclib, and Abemaciclib); By Route of Administration (Inhaled, Tablet, Liquid and Injection) and By End User (Hospitals, Clinics, Research Laboratories and Retail Pharmacies) – Global Demand Analysis & Opportunity Outlook 2028

  • Text Size:

Extensive insights into the Growth of CDK 4/6 Inhibitor Drugs Market amidst COVID-19

Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.

Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.

We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.

In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months.                                                         Request Insights

Read More


  • April 2019: Pfizer Inc. released a news statement that U.S. Food and Drug Administration (FDA) approved Ibrance (Palbociclib) for treatment of men with HR+, HER2- metastatic breast cancer.

Introduction to CDK 4/6 Inhibitor Drugs

CDK inhibitor drugs, also known as CDK (cyclin-dependent kinase) inhibitor is a type of chemical that restricts the function of CDKs. CDK 4/6 inhibitors are a class of drugs, also called (CDK4 and CDK6) that target enzymes. These enzymes are crucial in cell division. CDK 4/6 inhibitor plays a key role in regulating the replication and growth of breast cancer cells. The CDK 4/6 inhibitor drugs such as Palbociclib, Ribociclib, and Abemaciclib are used to treat metastatic breast cancer at an early stage.

Market Size and Forecast

Rising cases of patients with breast cancer owing to increasing exposure to risk factors such as carcinogens, sedentary lifestyles and pollution are the significant factors boosting the market growth. According to the statistics by the World Health Organization (WHO), it is estimated that 627000 women died from breast cancer in the year 2018. The growing concern for breast cancer globally and the need for treating such diseases are further anticipated to promote towards the growth of the global CDK 4/6 inhibitor drugs market. The CDK 4/6 inhibitor drugs market is anticipated to record a significant CAGR over the forecast period, i.e., 2020-2028. The market is segmented by end user into hospitals, clinics, research laboratories and retail pharmacies. Among these segments, the segment for hospitals is anticipated to hold the leading share in the market on account of availability of CDK 4/6 inhibitor drugs used for the patient’s treatment only at the hospital. The global CDK 4/6 inhibitor drugs market is further segmented by route of administration into inhaled, tablet, liquid and injection, out of which, the injection segment is anticipated to hold the largest market share owing to the increasing use of injections for treating breast cancer diseases. Healthcare specialists often prescribe the use of injections for delivering cancer drugs as it possesses numerous benefits over other dosage forms. Moreover, drug delivery through injections have been proved to be much more efficient as the drug is released directly to the blood stream in the body.

Growth Drivers

Rising Cases of Breast Cancer Globally to Boost the Market Growth

Breast cancer being the most common cancer among women, the need for advanced screening and treatment is increasing to cure it at an early stage. According to American Cancer Society, the chance that a woman will die from breast cancer is about 2.6% i.e. 1 in 38. The leading cause of high rates of cancer-related deaths in women is owing to the increased incidence of breast cancer. This factors attributes to the high demand for CDK 4/6 inhibitor drugs and is anticipated to significantly expand the CDK 4/6 inhibitor drugs market. CLICK TO DOWNLOAD SAMPLE REPORT

Huge Investment in Healthcare R&D to Drive the Market Growth

The healthcare development all over the world is improving at a fast pace owing to the increasing number of cases of various diseases which results in a growing demand for better healthcare services, facilities and equipment at clinics and hospitals. The growing research activities for treatment methods at research laboratories further fuels the healthcare industry. On the back of these, the market is predicted to grow over the forecast period.


High Cost and Side-Effects of Drugs to Hamper the Market Growth

Despite the improving healthcare infrastructure, there is a high cost involved with these drugs related to cancer treatment. Further, there are major side effects associated with this drugs post medication. This is estimated to hinder the growth of CDK 4/6 inhibitor drugs market in the future.

Market Segmentation

Our in-depth analysis of the CDK 4/6 inhibitor drugs market includes the following segments:

By Product Type

  • Palbociclib
  • Ribociclib
  • Abemaciclib

By Route of Administration

  • Inhaled
  • Tablet
  • Liquid
  • Injection

By End User

  • Hospitals
  • Clinics
  • Research Laboratories
  • Retail Pharmacies

By Region

On the basis of regional analysis, the CDK 4/6 inhibitor drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market for CDK 4/6 inhibitor drugs in North America is anticipated to hold the largest share in the market on account of presence of leading market players in the region which manufacture and market CDK 4/6 inhibitor drugs. Moreover, favorable reimbursement policies by the government in this region further increases the product demand. The market in Asia Pacific region is predicted to grow at the highest rate during the forecast period as a result of developing healthcare infrastructure and growing research activities in the region. Also, the rise in awareness about early diagnosis of diseases such as cancer in the region, especially in countries such as China, India and Japan further raise the demand for CDK 4/6 inhibitor drugs.

The CDK 4/6 inhibitor drugs market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis.
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis

Top Featured Companies Dominating the Market

Related Reports

Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2021 Research Nester. All Rights Reserved